Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
18.62
+0.85 (4.78%)
Nov 5, 2024, 4:00 PM EST - Market closed

Entrada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Nov '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Market Capitalization
655503424534--
Market Cap Growth
7.07%18.72%-20.71%---
Enterprise Value
220219236610--
Last Close Price
17.7715.0913.5217.12--
PE Ratio
12.01-74.60-4.47-2.10--
PS Ratio
2.933.90----
PB Ratio
1.572.081.991.79--
P/FCF Ratio
-32.203.75-4.38-9.64--
P/OCF Ratio
-40.263.60-4.52-10.51--
EV/Sales Ratio
1.021.69----
EV/EBITDA Ratio
3.59-680.70-2.48-12.19--
EV/EBIT Ratio
3.81-69.10-2.43-11.92--
EV/FCF Ratio
-8.991.63-2.44-11.00--
Debt / Equity Ratio
0.150.280.12---
Debt / EBITDA Ratio
0.814.68----
Debt / FCF Ratio
-3.510.51-0.27---
Asset Turnover
0.410.36----
Quick Ratio
6.402.268.6243.3211.628.77
Current Ratio
6.592.339.5544.4611.899.08
Return on Equity (ROE)
16.43%-2.94%-37.01%-30.19%-93.94%-
Return on Assets (ROA)
6.95%-0.55%-21.79%-18.29%-53.97%-
Return on Capital (ROIC)
9.03%-0.72%-22.63%-18.86%-59.03%-
Earnings Yield
8.79%-1.33%-22.33%-9.57%--
FCF Yield
-2.79%26.68%-22.82%-10.38%--
Buyback Yield / Dilution
-9.14%-5.61%-399.27%-467.09%-18.45%-
Total Shareholder Return
-9.14%-5.61%-399.27%-467.09%-18.45%-
Source: S&P Capital IQ. Standard template. Financial Sources.